C12N 2770/36123
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2770/36123 (Virus like particles [vlp]) appears on 59 US grants and 83 published applications in this corpus.
Search patents in C12N- Granted patents
- 59
- Published applications
- 83
- Assignees
- 49
- Inventors
- 107
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 3 | 3 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 5 |
| 2015 | 1 | 4 |
| 2016 | 7 | 8 |
| 2017 | 3 | 5 |
| 2018 | 4 | 3 |
| 2019 | 5 | 5 |
| 2020 | 3 | 7 |
| 2021 | 4 | 6 |
| 2022 | 5 | 5 |
| 2023 | 7 | 8 |
| 2024 | 4 | 4 |
| 2025 | 2 | 4 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Galectin-targeting immunotherapy26 May 2026US 12,636,341 B2VLP Therapeutics, LLC
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP33 Mar 2026US 12,564,625 B2Valneva SE
- Chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E1, and E2 structural proteins22 Apr 2025US 12,281,336 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Alphavirus replicon particle18 Feb 2025US 12,227,770 B2VLP Therapeutics, LLC
- Virus-like particles and methods of use17 Dec 2024US 12,168,675 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp320 Aug 2026US 2026/0240977 A1Valneva SE
- Nanobiosensor and preparation method thereof and virus antibody detection method using same13 Aug 2026US 2026/0235602 A1National Defense Medical University
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy2 Jul 2026US 2026/0183354 A2SunVax mRNA Therapeutics Inc.
- Virus like particle compositions and methods of use4 Jun 2026US 2026/0152728 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)5 Feb 2026US 2026/0034208 A1Yale University
Most cited
By later US patents
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019
- Ribonuclease resistant RNA preparation and utilization80US 5,939,262 AAmbion, Inc. · 1999
- Virus-like particles (VLPs) prepared from chikungunya virus structural proteins30US 9,353,353 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2016
- TC-83-derived alphavirus vectors, particles and methods24US 8,709,441 B2AlphaVax, Inc. · 2014
- Virus like particle composition22US 9,249,191 B2VLP Therapeutics, LLC · 2016